Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial

Ignacio Melero, Bernhard Reis, Corinne Rusterholz, Alexandra Epp, Nicole A. Kratochwil, Chun Wu, Michael Hettich, Georgios Kazantzidis, Natascha Rieder, Petra C. Schwalie, Solveig Badillo, Nadine Kumpesa, Andreas Thommen, Danielle J. Vugts, Victor Moreno, Julia Lostes Bardaji, Eduardo Castanon Alvarez, Carlos E. de Andrea, Iben Spanggaard, Dae Ho Lee, James Spicer, Fiona Thistlethwaite, Do-Youn Oh, Antoine Hollebecque, Olivera Cirovic, Stefan N. Symeonides

Open source

DOI: 10.1038/s43018-026-01157-8
Published: 2026-05-01
Container: Nature Cancer
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s43018-026-01157-8,
  title = {Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial},
  author = {Ignacio Melero and Bernhard Reis and Corinne Rusterholz and Alexandra Epp and Nicole A. Kratochwil and Chun Wu and Michael Hettich and Georgios Kazantzidis and Natascha Rieder and Petra C. Schwalie and Solveig Badillo and Nadine Kumpesa and Andreas Thommen and Danielle J. Vugts and Victor Moreno and Julia Lostes Bardaji and Eduardo Castanon Alvarez and Carlos E. de Andrea and Iben Spanggaard and Dae Ho Lee and James Spicer and Fiona Thistlethwaite and Do-Youn Oh and Antoine Hollebecque and Olivera Cirovic and Stefan N. Symeonides},
  year = {2026},
  journal = {Nature Cancer},
  doi = {10.1038/s43018-026-01157-8},
  url = {https://doi.org/10.1038/s43018-026-01157-8}
}

RIS

TY  - JOUR
TI  - Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial
AU  - Ignacio Melero
AU  - Bernhard Reis
AU  - Corinne Rusterholz
AU  - Alexandra Epp
AU  - Nicole A. Kratochwil
AU  - Chun Wu
AU  - Michael Hettich
AU  - Georgios Kazantzidis
AU  - Natascha Rieder
AU  - Petra C. Schwalie
AU  - Solveig Badillo
AU  - Nadine Kumpesa
AU  - Andreas Thommen
AU  - Danielle J. Vugts
AU  - Victor Moreno
AU  - Julia Lostes Bardaji
AU  - Eduardo Castanon Alvarez
AU  - Carlos E. de Andrea
AU  - Iben Spanggaard
AU  - Dae Ho Lee
AU  - James Spicer
AU  - Fiona Thistlethwaite
AU  - Do-Youn Oh
AU  - Antoine Hollebecque
AU  - Olivera Cirovic
AU  - Stefan N. Symeonides
PY  - 2026
JO  - Nature Cancer
DO  - 10.1038/s43018-026-01157-8
UR  - https://doi.org/10.1038/s43018-026-01157-8
ER  -

APA

Melero, I., Reis, B., Rusterholz, C., Epp, A., Kratochwil, N. A., Wu, C., Hettich, M., Kazantzidis, G., Rieder, N., Schwalie, P. C., Badillo, S., Kumpesa, N., Thommen, A., Vugts, D. J., Moreno, V., Bardaji, J. L., Alvarez, E. C., Andrea, C. E. D., Spanggaard, I., Lee, D. H., Spicer, J., Thistlethwaite, F., Oh, D., Hollebecque, A., Cirovic, O., & Symeonides, S. N. (2026). Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial. Nature Cancer. https://doi.org/10.1038/s43018-026-01157-8

Source records

crossref · retrieved 2026-09-26T19:46:15.520Z